Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters

Core Viewpoint - Curanex Pharmaceuticals Inc. has successfully completed its initial public offering (IPO), raising a total of $17.25 million through the sale of 4,312,500 shares, with an additional 562,500 shares sold under the over-allotment option at $4.00 per share [1][2]. Group 1: IPO Details - Dominari Securities LLC acted as the lead underwriter for the IPO, with Pacific Century Securities LLC and Revere Securities LLC serving as co-underwriters [3]. - The IPO was registered with the SEC under Form S-1 and was declared effective on August 12, 2025 [4]. Group 2: Company Overview - Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company based in Jericho, New York, focusing on botanical drugs for inflammatory diseases [6]. - The company's lead candidate, Phyto-N, is a botanical extract with anti-inflammatory properties, validated in animal models for six inflammatory diseases, primarily targeting moderate to severe ulcerative colitis [7].